Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

MLA

Thompson, Philip A., et al. “Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year.” Blood, vol. 140, no. Supplement 1, Nov. 2022, pp. 238–40. EBSCOhost, https://doi.org/10.1182/blood-2022-170030.

APA

Thompson, P. A., Keating, M. J., Ferrajoli, A., Jain, N., Peterson, C. B., Garg, N., Ayala, A., Hernandez, J. A., Kadia, T. M., Bose, P., Pemmaraju, N., Short, N., & Wierda, W. G. (2022). Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year. Blood, 140(Supplement 1), 238–240. https://doi.org/10.1182/blood-2022-170030

Chicago

Thompson, Philip A., Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Ana Ayala, et al. 2022. “Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year.” Blood 140 (Supplement 1): 238–40. doi:10.1182/blood-2022-170030.